From: Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones
Patient characteristics | AML pos for FLT3/ITD | AML neg for FLT3/ITD |
---|---|---|
No. of patients | 12 | 27 |
Male/female | 8/4 | 17/10 |
Age at diagnosis, median, (range) | 62 (23–73) | 69 (23–88) |
WBC count at diagnosis × 109/L, median (range) | 6.6 (0.9–179) | 6.3 (0.7–227) |
BM blasts % by morphology, median (range) | 72 (26–85) | 35 (20–87) |
AML de novo/secondary n (%) | 9 (75)/3 (25) | 23 (85)/4 (15) |
FAB classification, n (%) | ||
Mo | 0 (0) | 0 (0) |
M1 | 6 (50) | 2 (7) |
M2 | 1 (8) | 10 (37) |
M3 | 2 (17) | 2 (7) |
M4 | 1 (8) | 3 (11) |
M5 | 1 (8) | 4 (15) |
M6 | 0 (0) | 0 (0) |
M7 | 0 (0) | 0 (0) |
Not classified | 1 (8) | 6 (22) |
Cytogenetic risk group, n (%) | ||
Favorable | 2 (17) | 4 (15) |
Intermediate | 10 (83) | 13 (48) |
Poor | 0 (0) | 9 (33) |
Insufficient sample | 0 (0) | 1 (4) |
Induction therapy response, n (%) | ||
CR | 7 (70) | 15 (88) |
Failure | 3 (30) | 2 (12) |